Biomarker-based adaptive trials for patients with glioblastoma - Lessons from I-SPY 2

Neuro-Oncology

Volumn 15, Issue 8, 2013, Pages 972-978

  Alexander, Brian M ^a   Wen, Patrick Y ^a   Trippa, Lorenzo ^b   Reardon, David A ^a   Yung, Wai Kwan Alfred ^c   Parmigiani, Giovanni ^b   Berry, Donald A ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adaptive; Bayesian; biomarker; clinical trials; glioblastoma

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PROGESTERONE RECEPTOR; RINDOPEPIMUT; TEMOZOLOMIDE; TRASTUZUMAB;

ADAPTIVE BEHAVIOR; CANCER PATIENT; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HEALTH CARE PLANNING; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; TREATMENT RESPONSE;

ADAPTIVE; BAYESIAN; BIOMARKER; CLINICAL TRIALS; GLIOBLASTOMA;

BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; GLIOBLASTOMA; HUMANS; RESEARCH DESIGN;

EID: 84880694475     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not088     Document Type: Review

References (48)

1. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
2. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.
3. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2011;9(4):199-207.
4. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol. 2005;23(28):6982-6991.
5. FDA. Critical Path Initiative. http://www.fda.gov/ScienceResearch/ SpecialTopics/CriticalPathInitiative/ucm076689.htm. Accessed October 7, 2012.
6. FDA. Critical path opportunities report. 2006; http://www.fda.gov/ downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/UCM077254.pdf. Accessed May 8, 2013.
7. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol. 2011;29(6):606-609.
8. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY2: an adaptive breast cancer trial design in the setting of neo adjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100.
9. FDA. Guidance for industry: adaptive design clinical trials for drugs and biologics. 2010; http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm201790.pdf. Accessed May 8, 2013.
10. Meurer WJ, Lewis RJ, Tagle D, et al. An overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) project. Ann Emerg Med. 2012;60(4):451-457.
11. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Disc. 2011;1(1):44-53.
12. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res. 2012; 18(3):638-644.
13. Galanis E, Wu W, Cloughesy T, et al. Phase2trialdesigninneuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012; 13(5):e196-e204.
14. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8): 2443-2449.
15. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
16. Seymour L, Ivy SP, Sargent D, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the National Cancer Institute investigational drug steering committee. Clin Cancer Res. 2010;16(6):1764-1769.
17. Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci. 2004;19(1):175-187. (Pubitemid 39056885)
18. Berry DA, Eick SG. Adaptiveassignmentversusbalanced randomization in clinical trials: a decision analysis. Stat Med. 1995;14(3):231-246.
19. Berry DA. A case for Bayesianism in clinical trials. Stat Med. 1993;12(15-16):1377-1393; discussion 1395-1404.
20. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
21. Galanis E, Wu W, Sarkaria J, et al. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep. 2011;13(1):42-49.
22. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10): 997-1003. (Pubitemid 40349502)
23. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3): 157-173. (Pubitemid 43357943)
24. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110.
25. Colman H, Zhang L, Sulman EP, et al. Amultigene predictorofoutcome in glioblastoma. Neuro Oncol. 2010;12(1):49-57.
26. Alexander BM, Mehta MP. Role of isocitrate dehydrogenase in glioma. Expert Rev Neurother. 2011;11(10):1399-1409.
27. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type an-aplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
28. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
29. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7): 707-715.
30. Trippa L, Lee EQ, Wen PY, et al. Bayesianadaptiverandomized trialdesign for patients with recurrent glioblastoma. J Clin Oncol. 2012;30(26): 3258-3263.
31. FDA. Table of pharmacogenomic biomarkersindrug labels. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378.htm (accessed September 13, 2012).
32. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Exp Opin Biol Ther. 2009;9(8): 1087-1098.
33. Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park). 2002;16(10):1340-1348, 1351-1352; discussion 1352, 1355-1358.
34. Berry DA. Bayesian clinical trials. Nat Rev Drug Disc. 2006;5(1): 27-36.
35. Esserman LJ, Berry DA, Demichele A, et al. Pathologic complete response predicts recurrence-free survival more effectivelybycancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30(26):3242-3249.
36. Shahar T, Nossek E, Steinberg DM, et al. The impact of enrollment in clinical trials on survival of patients with glioblastoma. J Clin Neurosci. 2012;19(11):1530-1534.
37. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26(13):2192-2197.
38. Esserman LJ, Berry DA, Cheang MC, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132(3): 1049-1062.
39. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-170.
40. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010;12(3):274-282.
41. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9(1):29-38. (Pubitemid 46543486)
42. Hu LS, Eschbacher JM, Heiserman JE, et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosistopredict survival. Neuro Oncol. 2012;14(7):919-930.
43. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005;102(46):16759-16764. (Pubitemid 41688850)
44. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25(30):4714-4721. (Pubitemid 350086472)
45. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development - an executive summary of the PhRMA Working Group. J Biopharm Stat. 2006;16(3):275-283.
46. Foundation for the National Institutes of Health. The Biomarkers Consortium - cancer steering committee. http://www.biomarkers consortium.org/steering-cancer.php (accessed May 8, 2013).
47. Lee JJ, Chen N, Yin G. Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res. 2012;18(17): 4498-4507.
48. Couzin-Frankel J. FDA's $25 million pitch for improving drug regulation. Science Insider. 2010; http://news.sciencemag.org/scienceinsider/ 2010/10/fdas-25-million-pitch-for-improving.html0?. Accessed May 8, 2013.